Our goal is to verify HER2 status variability between primary tumor and metastatic site. Our second intention is to identify the most reliable criteria for pathological HER2 status assessment in gastric cancer node metastases since, at present, there is not a validated standard. 3 independent pathologists evaluated HER2 immunohistochemical and gene status (for IHC 2+ cases) in 34 gastric carcinoma metastatic lymph nodes and in their corresponding primary tumors. For primary gastric cancers, we followed the current HER2 assessment guidelines and for nodal metastases, we applied two immunohistochemical scoring systems with different cut-offs. The immunohistochemical inter-pathologists mean agreement was 71.4 % (κ = 0.45); a final score for each case was defined after collegial revision. By applying the two immunohistochemical criteria, we found 2 discordant cases, which can imply different pathological management. Moreover, a significantly different HER2 status between lymph node metastasis and primary tumor was obtained in 4 cases (concordance ratio 87.5 %). None of the patients would have undergone a different therapeutic pathway despite the scoring method applied. On the other hand we also detected a subset of patients who could have their therapeutic management changed, according to the differences between HER2 status in lymph nodes metastases and primary tumor. © 2012 Arányi Lajos Foundation.

Pagni, F., Zannella, S., Ronchi, S., Garanzini, C., Leone, B. (2013). HER2 Status of Gastric Carcinoma and Corresponding Lymph Node Metastasis. PATHOLOGY ONCOLOGY RESEARCH, 19(1), 103-109 [10.1007/s12253-012-9564-2].

HER2 Status of Gastric Carcinoma and Corresponding Lymph Node Metastasis

PAGNI, FABIO
;
LEONE, BIAGIO EUGENIO
2013

Abstract

Our goal is to verify HER2 status variability between primary tumor and metastatic site. Our second intention is to identify the most reliable criteria for pathological HER2 status assessment in gastric cancer node metastases since, at present, there is not a validated standard. 3 independent pathologists evaluated HER2 immunohistochemical and gene status (for IHC 2+ cases) in 34 gastric carcinoma metastatic lymph nodes and in their corresponding primary tumors. For primary gastric cancers, we followed the current HER2 assessment guidelines and for nodal metastases, we applied two immunohistochemical scoring systems with different cut-offs. The immunohistochemical inter-pathologists mean agreement was 71.4 % (κ = 0.45); a final score for each case was defined after collegial revision. By applying the two immunohistochemical criteria, we found 2 discordant cases, which can imply different pathological management. Moreover, a significantly different HER2 status between lymph node metastasis and primary tumor was obtained in 4 cases (concordance ratio 87.5 %). None of the patients would have undergone a different therapeutic pathway despite the scoring method applied. On the other hand we also detected a subset of patients who could have their therapeutic management changed, according to the differences between HER2 status in lymph nodes metastases and primary tumor. © 2012 Arányi Lajos Foundation.
Articolo in rivista - Articolo scientifico
HER2 gastric cancer
English
21-ago-2012
2013
19
1
103
109
open
Pagni, F., Zannella, S., Ronchi, S., Garanzini, C., Leone, B. (2013). HER2 Status of Gastric Carcinoma and Corresponding Lymph Node Metastasis. PATHOLOGY ONCOLOGY RESEARCH, 19(1), 103-109 [10.1007/s12253-012-9564-2].
File in questo prodotto:
File Dimensione Formato  
her 2 stomaco.pdf

accesso aperto

Dimensione 239.32 kB
Formato Adobe PDF
239.32 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/36011
Citazioni
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 21
Social impact